ライフサイエンスコーパス: poloxamer

1 estored to normal upon direct application of poloxamer.

2 crisis resolution was increased by purified poloxamer 188 (65/126 [52%] vs 45/123 [37%]; P =.02).

3 repair acutely with the non-ionic surfactant poloxamer 188 (P188) restored cell viability to control

4 The mechanism by which poloxamer 188 (P188) seals a damaged cell membrane is ex

5 These findings suggest that poloxamer 188 adsorbs into the lipid bilayers, thereby d

6 and that application of the membrane sealant poloxamer 188 corrects these defects in vitro.

7 s indicated an even more pronounced purified poloxamer 188 effect in children aged 15 years or younge

8 g to optimal dosing and long-term effects of poloxamer 188 in humans have been resolved, chemical-bas

9 fety and efficacy of adjunctive therapy with poloxamer 188 in patients receiving thrombolytic therapy

10 Purified poloxamer 188 may increase tissue oxygenation and thereb

11 c administration, and time to treatment with poloxamer 188 or placebo.

12 omized 114 patients to a 48-hour infusion of poloxamer 188 or vehicle placebo beginning immediately a

13 Adjunctive therapy with poloxamer 188 resulted in substantial benefit in this ra

14 In vivo administration of poloxamer 188 to dystrophic mice instantly improved vent

15 First, addition of a poloxamer 188 to nanoparticle formulations increased upt

16 Poloxamer 188 treatment also resulted in a reduced incid

17 Although the mechanisms are unproven, poloxamer 188 treatment may accelerate thrombolysis, red

18 Furthermore, addition of poloxamer 188 was found to reduce the membrane capacitan

19 Poloxamer 188 was well tolerated without adverse hemodyn

20 xo Wellcome Inc, Research Triangle Park, NC; poloxamer 188) Injection is a nonionic surfactant with h

21 RheothRx (poloxamer 188) is a surfactant with hemorheological and

22 receive an intravenous infusion of purified poloxamer 188, 100 mg/kg for 1 hour followed by 30 mg/kg

23 33 (41) hours in those treated with purified poloxamer 188, a 9-hour reduction (P =.04).

24 nic block co-polymeric surface active agent, poloxamer 188, on electroporation of artificial lipid me

25 articles (CGT-NP) prepared using gelatin and Poloxamer 188-grafted heparin copolymer demonstrated sig

26 bFGF-loaded NP (bFGF-NP) were prepared with Poloxamer 188-grafted heparin copolymer using water-in-w

27 charge pulse and voltage clamp experiments, poloxamer 188-treated membranes exhibited a statisticall

28 Also, poloxamer 188-treated membranes were found to have a rel

29 Poloxamer 188-treated patients demonstrated a 38% reduct

30 the symptoms were observed when the purified poloxamer 188-treated patients were compared with the pa

31 lipid bilayer of the type that are sealed by poloxamer 188.

32 eversed using the membrane sealant copolymer poloxamer 188.

33 membranes and membranes treated with 1.0 mM poloxamer 188.

34 crog/ml), poloxamine 908 (10-400 microg/ml), poloxamer 402 (20-400 microg/ml), and poloxamer 407 (10-

35 g/ml), poloxamer 402 (20-400 microg/ml), and poloxamer 407 (10-400 microg/ml).

36 established a novel mice model of HTG-AP by poloxamer 407 (P-407) combined with caerulein (Cae).

37 secretion, we injected the lipase inhibitor poloxamer 407 alone or before oral lipid gavage.

38 vel method based on a biocompatible polymer, poloxamer 407, which could significantly increase the vi

39 Poloxamer 407-coated nanocrystals containing the proteas

40 The optimized formulation was tested in poloxamer 407-induced hyperlipidemic rats.

41 S) intake from Aureobasidium pullulans using poloxamer-407 (PX-407) induced type 2 diabetes mellitus

42 esults showed that application of virus with poloxamer alone resulted in diffuse epicardial gene tran

43 hilic block copolymers based on PEO and PPO (Poloxamers and Pluronics) and advances in the area of PE

44 Poloxamers and poloxamine nonionic surfactants have dive

45 for quantitative determination of Pluronic (poloxamer) and Tetronic (poloxamine) macromolecules.

46 pylene oxide)-poly(ethylene oxide) (known as poloxamers) are typical examples of thermosensitive poly

47 Here, we show that Pluronic (Poloxamer) block copolymers are amenable to low-temperat

48 rdiac myocyte mechanical compliance and that poloxamer confers a highly effective membrane-stabilizin

49 immune responses and that is formulated with poloxamer CRL1005 and benzalkonium chloride to enhance i

50 tein B and phosphoprotein 65 formulated with poloxamer CRL1005 and benzalkonium chloride.

51 study to evaluate the safety and efficacy of poloxamer, formulated as RheothRx Injection, in 50 patie

52 al vectors to the epicardial surface, use of poloxamer gel to increase virus contact time, and mild t

53 insertion above 22 mN/m further suggests the poloxamer selectively adsorbs into damaged portions of e

54 reduction was likely to be that the viscous poloxamer solution blocked convection of viral vectors i

55 wn that chronic infusion of membrane-sealing poloxamer to severely affected dystrophic dogs reduced m

56 ormed on 23 membranes with 10 control and 13 poloxamer-treated membranes, and voltage pulse experimen

57 ments on 49 membranes with 26 control and 23 poloxamer-treated membranes.

58 Interestingly, after chronic poloxamer treatment, the poor compliance of isolated can

59 Investigational variables included poloxamer use, trypsin concentration, and safety.

60 ng a mechanism for the cell to be rid of the poloxamer when the membrane is restored.